NHS National Framework for Tocilizumab - March 2024

A Contract Award Notice
by NHS ENGLAND

Source
Find a Tender
Type
Framework (Supply)
Duration
1 year (est.)
Value
£60M
Sector
HEALTH
Published
08 Apr 2024
Delivery
01 Mar 2024 to 28 Feb 2025 (est.)
Deadline
n/a

Concepts

Location

Please refer to Document No. 10 in the ITO Documents for the list of Purchasing Points

Geochart for 2 buyers and 2 suppliers

2 buyers

2 suppliers

Description

Project Title: NHS National Framework for Tocilizumab - March 2024 Offer reference number: CM/PHR/23/5702CM/PHR/23/5702/01 NHS Framework for Tocilizumab LONDON and SOUTH OF ENGLAND. Period of framework: 1 March 2024 to 28 February 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. CM/PHR/23/5702/02 NHS Framework for Tocilizumab NORTH OF ENGLAND and MIDLANDS AND EAST. Period of framework: 1 March 2024 to 28 February 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.

Lot Division

1 CM/PHR/23/5702/01 NHS Framework for Tocilizumab LONDON and SOUTH OF ENGLAND

CM/PHR/23/5702/01 NHS Framework for Tocilizumab LONDON and SOUTH OF ENGLAND.
2 CM/PHR/23/5702/02 NHS Framework for Tocilizumab NORTH OF ENGLAND and MIDLANDS AN

CM/PHR/23/5702/02 NHS Framework for Tocilizumab NORTH OF ENGLAND and MIDLANDS AND EAST.

Award Detail

1 Roche Products (Welwyn Garden City)
  • NHS Framework for Tocilizumab LONDON and SOUTH OF ENGLAND
  • Num offers: 2
  • Value: £1
2 Fresenius Kabi (Cheshire)
  • NHS Framework for Tocilizumab LONDON and SOUTH OF ENGLAND
  • Num offers: 2
  • Value: £1

Renewal Options

There will be an option to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months

Award Criteria

PRICE _

CPV Codes

  • 33600000 - Pharmaceutical products

Indicators

  • Options are available.
  • Award on basis of price.

Reference

Domains